Comparing the outcomes pimecrolimus and mometasone cream in treatment of childhood vitiligo
Phase 3
- Conditions
- Vitiligo.Vitiligo
- Registration Number
- IRCT20230307057646N1
- Lead Sponsor
- Esfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 62
Inclusion Criteria
Vitiligo in less than 10 percent of body surface
non-segmental vitiligo
no history of allergic reaction to used drugs
Exclusion Criteria
pregnancy and lactating
using other treatments for vitiligo lesions in last 6 months
severe allergic reactions to used drugs
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Visual Analogue Scale score of improvement according to the patients. Timepoint: 3 months after the initiation of the treatments. Method of measurement: patients score the improvement from 1-10.;Mean changes in lesions size. Timepoint: 2 and 3 months after the initiation of the treatment. Method of measurement: millimeter sensitive ruler.;Pigmentation improvement in the lesions according to 2 experts. Timepoint: 2 and 3 months after the initiation of the treatment. Method of measurement: 2 experts in dermatology scoring the improvement from 0 to 3.
- Secondary Outcome Measures
Name Time Method